NR 565 ADVANCED PHARMACOLOGY
FINAL EXAM BANK
2026/2027 Examination
1|Page
,NR 565 ADVANCED PHARMACOLOGY FINAL EXAM BANK
2026/2027 Examination
Total Questions: 200
Instructions:
• Answer all questions.
• Select the single best answer.
• Each question has four answer choices: A, B, C, and D.
• Select only ONE answer for each question.
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1–30
Q1. A patient asks how a medication taken orally produces its effects throughout the body. The
advanced practice nurse explains that the study of how the body affects a drug through absorption,
distribution, metabolism, and excretion is known as:
A. Pharmacodynamics
B. Pharmacotherapeutics
C. Pharmacokinetics
D. Pharmacogenomics
Correct Answer: C. Pharmacokinetics
Rationale: Pharmacokinetics describes what the body does to a drug, encompassing the four
major processes of absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
refers to what the drug does to the body, including receptor interactions and therapeutic effects.
Pharmacotherapeutics is the clinical application of drugs to treat disease. Pharmacogenomics
examines how genetic variations influence individual drug responses.
Q2. A medication binds to a receptor and produces a submaximal response even when all
available receptors are occupied. This medication is best classified as a:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Correct Answer: B. Partial agonist
Rationale: A partial agonist has affinity for the receptor and produces some intrinsic activity, but
its maximal efficacy is lower than that of a full agonist even at full receptor occupancy. A full agonist
produces a maximal response. A competitive antagonist binds the receptor without activating it,
blocking agonist effects. An inverse agonist produces effects opposite to those of an agonist.
2|Page
, Q3. A patient is prescribed a drug that is a potent inducer of CYP450 enzymes. The advanced
practice nurse anticipates that concurrent medications metabolized by the same enzyme pathway
will exhibit:
A. Increased serum concentrations and potential toxicity
B. Decreased serum concentrations and potential therapeutic failure
C. Unchanged serum concentrations due to compensatory mechanisms
D. Prolonged half-life requiring extended dosing intervals
Correct Answer: B. Decreased serum concentrations and potential therapeutic failure
Rationale: CYP450 inducers increase the activity of metabolic enzymes, accelerating the
breakdown of drugs metabolized by that pathway. This results in lower serum concentrations and
possible loss of therapeutic effect. Common inducers include rifampin, phenytoin, carbamazepine,
and St. John's wort. Inhibitors, in contrast, decrease enzyme activity and raise drug levels.
Q4. Which of the following medications is a potent inhibitor of CYP450 enzymes, potentially
increasing serum levels of co-administered drugs?
A. Rifampin
B. Phenytoin
C. Carbamazepine
D. Ketoconazole
Correct Answer: D. Ketoconazole
Rationale: Ketoconazole is a potent CYP450 inhibitor that can significantly increase serum
concentrations of drugs metabolized by CYP3A4 and other pathways. Rifampin, phenytoin, and
carbamazepine are classic CYP450 inducers. A helpful mnemonic for inhibitors is "KICK":
Ketoconazole, Isoniazid, Cimetidine, and Grapefruit juice.
Q5. A drug with a narrow therapeutic index requires:
A. Less frequent monitoring because effects are predictable
B. Close monitoring of serum drug levels to avoid toxicity
C. No special precautions if the patient is adherent
D. Higher initial doses to achieve rapid therapeutic effect
Correct Answer: B. Close monitoring of serum drug levels to avoid toxicity
Rationale: Drugs with a narrow therapeutic index have a small margin between therapeutic and
toxic concentrations. Therapeutic drug monitoring is essential to maintain levels within the
therapeutic window. Examples include digoxin, lithium, warfarin, theophylline, and phenytoin. These
drugs require individualized dosing and frequent monitoring.
3|Page
, Q6. A 68-year-old patient with cirrhosis is prescribed a medication that undergoes extensive
first-pass hepatic metabolism. The advanced practice nurse anticipates that the bioavailability of this
medication will be:
A. Decreased due to impaired gastrointestinal absorption
B. Increased due to reduced first-pass metabolism
C. Unchanged because first-pass metabolism occurs primarily in the intestines
D. Variable depending entirely on renal function
Correct Answer: B. Increased due to reduced first-pass metabolism
Rationale: In cirrhosis, damaged hepatocytes and portosystemic shunting reduce first-pass
metabolism, allowing more unchanged drug to reach systemic circulation. This increases
bioavailability and raises the risk of toxicity. Dose reduction is often necessary for drugs with
extensive first-pass metabolism when hepatic function is impaired.
Q7. A patient is taking warfarin and is newly prescribed amiodarone. The advanced practice
nurse recognizes that this interaction increases bleeding risk through which mechanism?
A. Amiodarone induces CYP450 enzymes, increasing warfarin metabolism
B. Amiodarone inhibits CYP2C9, reducing warfarin metabolism
C. Amiodarone displaces warfarin from plasma protein binding sites
D. Amiodarone reduces warfarin absorption from the gastrointestinal tract
Correct Answer: B. Amiodarone inhibits CYP2C9, reducing warfarin metabolism
Rationale: Amiodarone is a potent inhibitor of CYP2C9 and CYP3A4, enzymes responsible for
warfarin metabolism. This inhibition leads to increased warfarin serum levels, elevated INR, and
heightened bleeding risk. When amiodarone is initiated, warfarin doses often require reduction by
30–50% with close INR monitoring.
Q8. A patient with reduced creatinine clearance of 32 mL/min is prescribed gentamicin. The
advanced practice nurse adjusts the dosing interval rather than the dose based on which
pharmacokinetic principle?
A. Decreased renal elimination prolongs half-life, requiring longer intervals
B. Renal impairment increases volume of distribution
C. Reduced kidney function enhances hepatic metabolism of aminoglycosides
D. Impaired renal function increases gastrointestinal absorption
Correct Answer: A. Decreased renal elimination prolongs half-life, requiring longer intervals
Rationale: Gentamicin is eliminated almost entirely by renal glomerular filtration. In renal
impairment, elimination is prolonged, extending the half-life. Extending the dosing interval allows
adequate drug elimination between doses, preventing accumulation and toxicity while maintaining
therapeutic peak concentrations.
4|Page
FINAL EXAM BANK
2026/2027 Examination
1|Page
,NR 565 ADVANCED PHARMACOLOGY FINAL EXAM BANK
2026/2027 Examination
Total Questions: 200
Instructions:
• Answer all questions.
• Select the single best answer.
• Each question has four answer choices: A, B, C, and D.
• Select only ONE answer for each question.
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1–30
Q1. A patient asks how a medication taken orally produces its effects throughout the body. The
advanced practice nurse explains that the study of how the body affects a drug through absorption,
distribution, metabolism, and excretion is known as:
A. Pharmacodynamics
B. Pharmacotherapeutics
C. Pharmacokinetics
D. Pharmacogenomics
Correct Answer: C. Pharmacokinetics
Rationale: Pharmacokinetics describes what the body does to a drug, encompassing the four
major processes of absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
refers to what the drug does to the body, including receptor interactions and therapeutic effects.
Pharmacotherapeutics is the clinical application of drugs to treat disease. Pharmacogenomics
examines how genetic variations influence individual drug responses.
Q2. A medication binds to a receptor and produces a submaximal response even when all
available receptors are occupied. This medication is best classified as a:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Correct Answer: B. Partial agonist
Rationale: A partial agonist has affinity for the receptor and produces some intrinsic activity, but
its maximal efficacy is lower than that of a full agonist even at full receptor occupancy. A full agonist
produces a maximal response. A competitive antagonist binds the receptor without activating it,
blocking agonist effects. An inverse agonist produces effects opposite to those of an agonist.
2|Page
, Q3. A patient is prescribed a drug that is a potent inducer of CYP450 enzymes. The advanced
practice nurse anticipates that concurrent medications metabolized by the same enzyme pathway
will exhibit:
A. Increased serum concentrations and potential toxicity
B. Decreased serum concentrations and potential therapeutic failure
C. Unchanged serum concentrations due to compensatory mechanisms
D. Prolonged half-life requiring extended dosing intervals
Correct Answer: B. Decreased serum concentrations and potential therapeutic failure
Rationale: CYP450 inducers increase the activity of metabolic enzymes, accelerating the
breakdown of drugs metabolized by that pathway. This results in lower serum concentrations and
possible loss of therapeutic effect. Common inducers include rifampin, phenytoin, carbamazepine,
and St. John's wort. Inhibitors, in contrast, decrease enzyme activity and raise drug levels.
Q4. Which of the following medications is a potent inhibitor of CYP450 enzymes, potentially
increasing serum levels of co-administered drugs?
A. Rifampin
B. Phenytoin
C. Carbamazepine
D. Ketoconazole
Correct Answer: D. Ketoconazole
Rationale: Ketoconazole is a potent CYP450 inhibitor that can significantly increase serum
concentrations of drugs metabolized by CYP3A4 and other pathways. Rifampin, phenytoin, and
carbamazepine are classic CYP450 inducers. A helpful mnemonic for inhibitors is "KICK":
Ketoconazole, Isoniazid, Cimetidine, and Grapefruit juice.
Q5. A drug with a narrow therapeutic index requires:
A. Less frequent monitoring because effects are predictable
B. Close monitoring of serum drug levels to avoid toxicity
C. No special precautions if the patient is adherent
D. Higher initial doses to achieve rapid therapeutic effect
Correct Answer: B. Close monitoring of serum drug levels to avoid toxicity
Rationale: Drugs with a narrow therapeutic index have a small margin between therapeutic and
toxic concentrations. Therapeutic drug monitoring is essential to maintain levels within the
therapeutic window. Examples include digoxin, lithium, warfarin, theophylline, and phenytoin. These
drugs require individualized dosing and frequent monitoring.
3|Page
, Q6. A 68-year-old patient with cirrhosis is prescribed a medication that undergoes extensive
first-pass hepatic metabolism. The advanced practice nurse anticipates that the bioavailability of this
medication will be:
A. Decreased due to impaired gastrointestinal absorption
B. Increased due to reduced first-pass metabolism
C. Unchanged because first-pass metabolism occurs primarily in the intestines
D. Variable depending entirely on renal function
Correct Answer: B. Increased due to reduced first-pass metabolism
Rationale: In cirrhosis, damaged hepatocytes and portosystemic shunting reduce first-pass
metabolism, allowing more unchanged drug to reach systemic circulation. This increases
bioavailability and raises the risk of toxicity. Dose reduction is often necessary for drugs with
extensive first-pass metabolism when hepatic function is impaired.
Q7. A patient is taking warfarin and is newly prescribed amiodarone. The advanced practice
nurse recognizes that this interaction increases bleeding risk through which mechanism?
A. Amiodarone induces CYP450 enzymes, increasing warfarin metabolism
B. Amiodarone inhibits CYP2C9, reducing warfarin metabolism
C. Amiodarone displaces warfarin from plasma protein binding sites
D. Amiodarone reduces warfarin absorption from the gastrointestinal tract
Correct Answer: B. Amiodarone inhibits CYP2C9, reducing warfarin metabolism
Rationale: Amiodarone is a potent inhibitor of CYP2C9 and CYP3A4, enzymes responsible for
warfarin metabolism. This inhibition leads to increased warfarin serum levels, elevated INR, and
heightened bleeding risk. When amiodarone is initiated, warfarin doses often require reduction by
30–50% with close INR monitoring.
Q8. A patient with reduced creatinine clearance of 32 mL/min is prescribed gentamicin. The
advanced practice nurse adjusts the dosing interval rather than the dose based on which
pharmacokinetic principle?
A. Decreased renal elimination prolongs half-life, requiring longer intervals
B. Renal impairment increases volume of distribution
C. Reduced kidney function enhances hepatic metabolism of aminoglycosides
D. Impaired renal function increases gastrointestinal absorption
Correct Answer: A. Decreased renal elimination prolongs half-life, requiring longer intervals
Rationale: Gentamicin is eliminated almost entirely by renal glomerular filtration. In renal
impairment, elimination is prolonged, extending the half-life. Extending the dosing interval allows
adequate drug elimination between doses, preventing accumulation and toxicity while maintaining
therapeutic peak concentrations.
4|Page
